Cargando…

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies

Detalles Bibliográficos
Autores principales:	Cheng, Lin, Song, Shuo, Fan, Qing, Shen, Senlin, Wang, Haiyan, Zhou, Bing, Ge, Xiangyang, Ju, Bin, Zhang, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608826/ https://www.ncbi.nlm.nih.gov/pubmed/34811350 http://dx.doi.org/10.1038/s41421-021-00347-1

Ejemplares similares

Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
por: Guo, Huimin, et al.
Publicado: (2022)

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
por: Ju, Bin, et al.
Publicado: (2022)

Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
por: Zhang, Yanjun, et al.
Publicado: (2023)

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
por: Wu, Kai, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
por: Zhou, Bing, et al.
Publicado: (2022)

Two long-lasting human monoclonal antibodies cross-react with monkeypox virus A35 antigen
por: Zhou, Bing, et al.
Publicado: (2023)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
por: Ju, Bin, et al.
Publicado: (2023)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo
por: Wang, Qianran, et al.
Publicado: (2022)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes
por: Cheng, Lin, et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma
por: Spencer, Andrew, et al.
Publicado: (2019)

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
por: Uriu, Keiya, et al.
Publicado: (2021)

Limits of Monoclonal Antibody Treatment in Pregnant Women Complicated with COVID-19 Due to The Omicron Variant
por: Cha, Hyun-Hwa, et al.
Publicado: (2022)

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
por: Li, Yang, et al.
Publicado: (2020)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
por: Liu, Yubin, et al.
Publicado: (2023)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
por: Mi, Taotao, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies
por: Ng, Weng M., et al.
Publicado: (2022)

Increased risk of hospitalisation and death with the delta variant in the USA
por: Bast, Elizabeth, et al.
Publicado: (2021)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
por: Peng, Weiyu, et al.
Publicado: (2023)

Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains
por: Pan, Ting, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants
por: Brehm, Thomas Theo, et al.
Publicado: (2022)

Hospitalisation associated with SARS-CoV-2 delta variant in Denmark
por: Bager, Peter, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ncfdp0fim8tiq3r4cdvi147fhn